Sander S van Leeuwen1, Evelien M Te Poele2, Anastasia Chrysovalantou Chatziioannou2, Eric Benjamins3, Alfred Haandrikman3, Lubbert Dijkhuizen2,4. 1. Department of Laboratory Medicine, Cluster Human Nutrition and Health, University Medical Center Groningen (UMCG), Hanzeplein 1, 9713 GZ Groningen, Netherlands. 2. CarbExplore Research BV, 9747 AN Groningen, Netherlands. 3. Ausnutria BV, 8025 BM Zwolle, Netherlands. 4. Department of Microbial Physiology, Groningen Biomolecular Sciences and Biotechnology Institute (GBB), University of Groningen, 9700 AB Groningen, Netherlands.
Abstract
Human milk is considered the golden standard in infant nutrition. Free oligosaccharides in human milk provide important health benefits. These oligosaccharides function as prebiotics, immune modulators, and pathogen inhibitors and were found to improve barrier function in the gut. Infant formulas nowadays often contain prebiotics but lack the specific functions of human milk oligosaccharides (hMOS). Milk from domesticated animals also contains milk oligosaccharides but at much lower levels and with less diversity. Goat milk contains significantly more oligosaccharides (gMOS) than bovine (bMOS) or sheep (sMOS) milk and also has a larger diversity of structures. This review summarizes structural studies, revealing a diversity of up to 77 annotated gMOS structures with almost 40 structures fully characterized. Quantitative studies of goat milk oligosaccharides range from 60 to 350 mg/L in mature milk and from 200 to 650 mg/L in colostrum. These levels are clearly lower than in human milk (5-20 g/L) but higher than in other domesticated dairy animals, e.g., bovine (30-60 mg/L) and sheep (20-40 mg/L). Finally, the review focuses on demonstrated and potential functionalities of gMOS. Some studies have shown anti-inflammatory effects of mixtures enriched in gMOS. Goat MOS also display prebiotic potential, particularly in stimulating growth of bifidobacteria preferentially. Although functional studies of gMOS are still limited, several structures are also found in human milk and have known functions as immune modulators and pathogen inhibitors. In conclusion, goat milk constitutes a promising alternative source for milk oligosaccharides, which can be used in infant formula.
Human milk is considered the golden standard in infant nutrition. Free oligosaccharides in human milk provide important health benefits. These oligosaccharides function as prebiotics, immune modulators, and pathogen inhibitors and were found to improve barrier function in the gut. Infant formulas nowadays often contain prebiotics but lack the specific functions of humanmilk oligosaccharides (hMOS). Milk from domesticated animals also contains milk oligosaccharides but at much lower levels and with less diversity. Goat milk contains significantly more oligosaccharides (gMOS) than bovine (bMOS) or sheep (sMOS) milk and also has a larger diversity of structures. This review summarizes structural studies, revealing a diversity of up to 77 annotated gMOS structures with almost 40 structures fully characterized. Quantitative studies of goatmilk oligosaccharides range from 60 to 350 mg/L in mature milk and from 200 to 650 mg/L in colostrum. These levels are clearly lower than in human milk (5-20 g/L) but higher than in other domesticated dairy animals, e.g., bovine (30-60 mg/L) and sheep (20-40 mg/L). Finally, the review focuses on demonstrated and potential functionalities of gMOS. Some studies have shown anti-inflammatory effects of mixtures enriched in gMOS. GoatMOS also display prebiotic potential, particularly in stimulating growth of bifidobacteria preferentially. Although functional studies of gMOS are still limited, several structures are also found in human milk and have known functions as immune modulators and pathogen inhibitors. In conclusion, goat milk constitutes a promising alternative source for milk oligosaccharides, which can be used in infant formula.
Entities:
Keywords:
goat milk oligosaccharides; health benefits; prebiotics; quantitative analysis; structures
The
composition of human milk is very different from that of domesticated
dairy animals (Figure ).[1−6] One of the major components, humanmilk oligosaccharides (hMOS),
constitutes a relatively large part of the carbohydrates present in
mother’s milk (5–20 g/L),[3,7] representing
up to 20% of the total carbohydrate content. The diversity of hMOS
is large, with 247 varieties observed and 162 hMOS structurally characterized.[8] The composition and abundance of hMOS vary between
women with the genetics of the mothers and during lactation,[9−12] but also evidence emerges that gestational age, maternal health
status, infant sex, and dietary habits influence hMOS composition.[11,13,14] These hMOS play a role in steering
a healthy development of the infant gut microbiome, acting as prebiotics,
stimulating the growth of beneficial bacteria. Beneficial bacteria
growing on prebiotics secrete short-chain fatty acid (SCFA) and other
metabolites (postbiotics), having a beneficial effect on host health.[15] Although other prebiotics are added to infant
formula, such as galactooligosaccharides (GOS) and fructooligosaccharides
(FOS), hMOS have well-established and specific functionalities. Oligosaccharides
in human milk have been found to inhibit pathogen adhesion, stimulate
the immune system of infants, modulate host receptors, and modify
epithelial glycosylation as well as stimulating brain development.[16,17] Some of these functions have also been observed for GOS in a few
studies, particularly stimulating gut barrier function, but have been
less well-established.[18−21]
Figure 1
Major
milk components (g/L), fat, lactose, casein, and whey, in
human (blue), goat (green), cow (purple) and sheep (red) milk, compiled
from available literature sources.[1,2,4−6]
Major
milk components (g/L), fat, lactose, casein, and whey, in
human (blue), goat (green), cow (purple) and sheep (red) milk, compiled
from available literature sources.[1,2,4−6]Bovine milk is traditionally the base for infant formula, as a
substitute for mother’s milk when breastfeeding is not possible
or mothers choose not to breastfeed. There are fewer studies of bovinemilk oligosaccharides (bMOS) than of hMOS, but the overall view is
that bMOS concentrations are much lower (30–60 mg/L) compared
to hMOS (5–20 g/L).[3,22] Moreover, the bMOS
composition with 40–50 varieties observed and 37 structures
identified is much less varied[23,24] than the hMOS composition
(∼247 varieties with 162 structures identified).[8] Goat milk is an approved protein source for infant
formula and has attracted attention as a result of higher levels and
diversity in milk oligosaccharides, with average concentrations reported
of 60–350 mg/L in mature milk and up to 2.4 g/L in colostrum.[25−30] The oligosaccharide composition of goat milk (gMOS) has been studied[24,27−29,31−35] and compared to other domesticated animals.[24,29] A few studies have reported variations of oligosaccharides at the
goat breed level,[25,26] over time during lactation,[25,28,36] in parity,[26] or at the individual goat level.[37] Such information is considered interesting, because gMOS are more
abundant than bMOS and contain certain structures that are in common
with hMOS (Schemes and 2). Therefore, goat milk has potential
to display special functional properties that may find application
in a range of commercial products in various niches.
Scheme 1
Overview
of All Neutral gMOS Structures Reported in Goat Colostrum
and Milk, with Relative Abundances Reported in Neutral and Acidic
Pools, Respectively
The hMOS column (Y/N) indicates
whether the structure has been observed in human milk. Hypothetical
interactions with galectins are indicated, according to Urashima et
al.[8] Possible interaction epitopes are
marked green; blocked epitopes are marked red; and gray boxes indicate
uncertain interactions where exact structures are not known, with
relative peak intensities in the neutral and acidic pool, respectively
(on the basis of the study by Albrecht et al.[24]).
Scheme 2
Overview of All Acidic gMOS Structures Reported
in Goat Colostrum
and Milk, with Relative Abundances Reported in Neutral and Acidic
Pools, Respectively
The hMOS column (Y/N) indicates
whether the structure has been observed in human milk. Hypothetical
interactions with galectins are indicated, according to Urashima et
al.[8] Possible interaction epitopes are
marked green; blocked epitopes are marked red; and gray boxes indicate
uncertain interactions where exact structures are not known, with
relative peak intensities in the neutral and acidic pool, respectively
(on the basis of the study by Albrecht et al.[24]).
Overview
of All Neutral gMOS Structures Reported in Goat Colostrum
and Milk, with Relative Abundances Reported in Neutral and Acidic
Pools, Respectively
The hMOS column (Y/N) indicates
whether the structure has been observed in human milk. Hypothetical
interactions with galectins are indicated, according to Urashima et
al.[8] Possible interaction epitopes are
marked green; blocked epitopes are marked red; and gray boxes indicate
uncertain interactions where exact structures are not known, with
relative peak intensities in the neutral and acidic pool, respectively
(on the basis of the study by Albrecht et al.[24]).
Overview of All Acidic gMOS Structures Reported
in Goat Colostrum
and Milk, with Relative Abundances Reported in Neutral and Acidic
Pools, Respectively
The hMOS column (Y/N) indicates
whether the structure has been observed in human milk. Hypothetical
interactions with galectins are indicated, according to Urashima et
al.[8] Possible interaction epitopes are
marked green; blocked epitopes are marked red; and gray boxes indicate
uncertain interactions where exact structures are not known, with
relative peak intensities in the neutral and acidic pool, respectively
(on the basis of the study by Albrecht et al.[24]).In this literature overview, we will evaluate
the current knowledge
of gMOS structures and quantities, also in relation to what is known
about hMOS and bMOS. An overview will be presented on functional properties
of MOS in general as well as specific structure–function relationships
that have been discovered thus far for hMOS, bMOS, and gMOS.
Goat Milk
Oligosaccharide (gMOS) Structures
The first gMOS were separated
and purified from Japanese Saanengoat colostrum.[31] Detailed structural characterization
identified three novel compounds, Gal(α1–3)Gal(β1–4)Glc
(α3′-GL), Gal(β1–3)Gal(β1–4)Glc
(3′-GL), Gal(β1–6)Gal(β1–4)Glc (6′-GL),
and Fuc(α1–2)Gal(β1–4)Glc (2′-FL).[31] In 1997, the same research group reported the
structures of the first four acidic gMOS from Japanese Saanen, namely,
Neu5Ac(α2–6)Gal(β1–4)Glc (6′-SL),
Neu5Ac(α2–3)Gal(β1–4)Glc (3′-SL),
Neu5Gc(α2–6)Gal(β1–4)Glc (6′-NGL),
and Neu5Ac(α2–6)Gal(β1–4)GlcNAc (6′-SLN).[33] This study showed non-humansialic acid N-glycolylneuraminic acid (Neu5Gc) occurring in gMOS.[33] Another group published the structures of two
branched acidic gMOS from mature goat milk, i.e., Gal(β1–3)[Neu5Ac(α2–6)]Gal(β1–4)Glc
(6′-SHL) and Gal(β1–6)[Neu5Ac(α2–3)]Gal(β1–4)Glc
(3′-SHL).[32]After these initial
efforts to isolate specific oligosaccharides
from goat milk and to identify their structures with detailed analytical
methods, more comprehensive studies were performed, identifying structural
compositions, i.e., the monosaccharide makeup of the structures, based
on mass spectrometry (MS) data. When these data were combined with
reference structures and previous literature, comparative studies
could be made, following known structures and annotating newly found
oligosaccharide structures. One of the first comparative studies focused
on the gMOS composition of fresh mature milk from Spanish goats from
the Murciano-Granadina breed, from cows and sheep, compared to hMOS.[29]A detailed and comprehensive study was
conducted by Albrecht et
al., in which milk samples of different domesticated animals, including
goats, were analyzed for their milk oligosaccharide composition.[24] Structural oligosaccharide libraries were created
using a combination of analytical techniques. Purified MOS were fluorescently
derivatized via reductive amination with 2-aminobenzamide (2-AB).
This stoichiometric addition of one 2-AB label per oligosaccharide
allowed for their relative quantification with fluorescence detection.[38] Some oligosaccharides were identified on the
basis of their elution compared to standards. All other structures
were identified by exoglycosidase assays in combination with tandem
mass spectrometry (MS/MS) data. Sialic acid determination was performed
to distinguish between Neu5Gc and Neu5Ac epitopes.[31]Albrecht et al. found that milk from domesticated
animals contained
a much larger variety in complex MOS than previously known. More than
80% of the oligosaccharides found in pools of all domesticated animals
were acidic oligosaccharides. In total, 77 structures were identified
in all of the milk samples, of which 29 were neutral, 45 were sialylated,
and 3 were phosphorylated.[24] A total of
40 structures were characterized in mature goat milk, of which 16
were neutral, 23 were acidic, and 1 was phosphorylated lactose (Schemes and 2). Numerically, sheep and bovine milk are only
slightly less diverse, with 37 and 32 distinct structures, respectively.
However, in comparison of the total milk profile, bovine milk is dominated
by one structure, i.e., 3′-SL, while sheep milk is dominated
by 3′-N-glycolylneuraminyllactose (3′-NGL)
and 6′-N-glycolylneuraminyllactose (6′-NGL)
and goat milk shows a much more varied peak pattern in this comparative
study.[24] From the sialylated pool, the
proportion of Neu5Gc-containing oligosaccharides was highest in sheep
colostrum (94%) and mature goat milk (64%). The acidic pool of cow
colostrum contained 3% Neu5Gc oligosaccharides, whereas only trace
amounts were found in the milk of other domesticated animals (≤1%).[24] Humans are unique in their inability to produce
Neu5Gc but are able to incorporate dietary Neu5Gc in their glycosylation.[39,40] Incorporation of Neu5Gc has also been observed in hMOS.[41] Studies have associated Neu5Gc incorporation
with several diseases, including cancer, type 2 diabetes, atherosclerosis,
and autoimmune diseases.[40,42] Although there is no
causality proven for Neu5Gc, potential health effects of the relatively
high levels of Neu5Gc in goat milk should be taken into account. In
the study by Albrecht et al., 19 structures were identified for the
first time in goat milk along with 3-FL, one of the more abundant
hMOS constituents.[24] A later study annotated
78 variations in goat colostrum but did not identify specific structures;
only monosaccharide compositional data were obtained.[37]Using more sensitive techniques, a comparative study
between αs1-casein-producing and non-producing goats
was performed.[27] Previously reported structure
compositions were
observed and verified by MS/MS. This study annotated in total 37 oligosaccharide
structures. A fucosyllactosamine structure with monosaccharide composition
1Hex, 1Fuc, 1HexNAc, 0Neu5Ac, and 0Neu5Gc was exclusively found in
milk of goats unable to synthesize αs1-casein. Another
fucosylated gMOS composed of 3Hex, 1Fuc, 3HexNAc, 0Neu5Ac, and 0Neu5Gc
was present in both types of milk but only in trace amounts in milk
of αs1-casein-producing goats. For all other structures,
no significant differences in abundance were observed.Taken
together, the structural diversity of human milk is much
higher than that of any domesticated dairy animal, i.e., 247 compositional
variations and 162 identified structures in human milk, as compared
to 78 compositions and 40 structures in goat milk, 50 compositions
and 37 structures in bovine milk, and 32 structures in sheep milk;
as a result of fewer studies, there is no extra data on composition
variety in sheep milk at this time.[8,23,24,37] With focus on the major
structures that are responsible for >95% of the quantitative composition
on the basis of relative abundance studies, human milk contains 22
major structures,[3,43] while goat milk is defined by
9 major structures, bovine milk is defined by 6 structures, and sheep
milk is defined by only 4.[24] It is clear
that goat milk presents a more diverse pallet of MOS structures than
bovine or sheep milk.There are some clear differences in the
structural composition
and number of oligosaccharides between human milk and milk from domesticated
animals, e.g., goat, cow, and sheep.[24] In
human milk, the lacto-N-biose type 1 structural epitope
predominates over those containing the N-acetyllactosamine
type 2 structure (Figure ), whereas type 1 chains are rare in milk of domesticated
dairy animals. Contrary to hMOS, domesticated animal milk oligosaccharides
can also have N-acetyllactosamine [Gal(β1–4)GlcNAc]
at the reducing end.[44] Around 70% of hMOS
is neutral and often fucosylated,[24] whereas
the fraction of fucosylated MOS in animal milk is relatively low and
most of the oligosaccharides are acidic.[44,45] Domesticated animal milk can contain structural epitopes that are
not present in human milk, such as GalNAc, Neu5Gc-containing oligosaccharides,
and (α1–3)-linked Gal and GalNAc.[24] Moreover, in goat as well as bovinemilk oligosaccharides,
Gal(β1–4)GlcNAc branches on 3′-galactosyllactose
(lacto-N-novopentaose) have been observed as well
as sialylation of both 3′-GL as well as 6′-GL (Schemes and 2).
Figure 2
Biosynthesis of neutral and acidic complex (left) human
milk oligosaccharides
(hMOS) and (right) goat milk oligosaccharides (gMOS). Enzymes probably
involved are indicated in the human pathway. Required enzyme activities
to achieve known structures are notated in the goat pathway. Iβ6GlcNAcTx
refers to a potential separate enzyme as observed in marsupial lactation,
capable of adding GlcNAc(β1–6) branching of 3′-GL.[57] Main pathways and structure types are depicted
in bold with thicker arrows. The human hypothetical pathway is compiled
from Urashima et al.,[8] Bode et al.,[16] Blank et al.,[54] and
Van Leeuwen et al.[53] and combined with
the Kyoto Encyclopedia of Genes and Genomes (KEGG) glycosphingolipid
biosynthesis: lacto and neolacto series.[56]
Biosynthesis of neutral and acidic complex (left) humanmilk oligosaccharides
(hMOS) and (right) goatmilk oligosaccharides (gMOS). Enzymes probably
involved are indicated in the human pathway. Required enzyme activities
to achieve known structures are notated in the goat pathway. Iβ6GlcNAcTx
refers to a potential separate enzyme as observed in marsupial lactation,
capable of adding GlcNAc(β1–6) branching of 3′-GL.[57] Main pathways and structure types are depicted
in bold with thicker arrows. The human hypothetical pathway is compiled
from Urashima et al.,[8] Bode et al.,[16] Blank et al.,[54] and
Van Leeuwen et al.[53] and combined with
the Kyoto Encyclopedia of Genes and Genomes (KEGG) glycosphingolipid
biosynthesis: lacto and neolacto series.[56]In bovine milk, N-linked glycans
from glycoproteins were shown
to contain N,N′-di-N-acetyllactose diamine [GalNAc(β1–4)GlcNAc
(LacdiNAc)].[46] Although no comprehensive
studies of goat milk protein glycosylation are known to us, a recombinant
humanerythropoietin expressed in transgenic goat milk was highly
decorated with the LacdiNAc epitope.[47] In
bovine milk, LacdiNAc disaccharide has been observed as well as other
oligosaccharides where Gal has been substituted for GalNAc.[38,48] This activity has been ascribed to bovine α-lactalbumin, which
induces milk β-galactosyltransferase (B4GalT1) to accept uridine
diphosphate (UDP)–GalNAc as a donor as well as UDP–Gal
in the synthesis of lactose.[49] It is not
known whether this is also responsible for the LacdiNAc glycotope
in protein glycosylation. Possibly β-N-acetylgalactosaminyltransferases
B4GalNT3 and B4GalNT4 are responsible for the synthesis of these glycotopes.
It should be noted that, in humans, these enzymes are also encoded
in the genome and are responsible for the presence of LacdiNAc epitopes
in the gastric mucosa.[50] In view of the
similarities between MOS and protein glycosylation patterns, such
LacdiNAc glycotopes can also be expected to occur in bMOS and gMOS.The α-Gal glycotope is found abundantly in mammalian glycosylation,
except for humans, apes, and Old World monkeys.[51] The responsible enzyme α-galactosyltransferase (GGTA1)
is functionally encoded in the genomes of most mammals. In the human
genome, two non-functional variants have been identified, GGTA1 and
GGTA1P.[52]From the structures known
thus far (Schemes and 2), it is possible
to construct a hypothetical biosynthetic scheme for gMOS, as presented
previously for hMOS (Figure ).[53,54] Although for gMOS the biosynthetic
enzymes are less established, many of the enzymes postulated to be
involved in hMOS biosynthesis have homologues in the goat genome that
are also expressed in the mammary gland during lactation.[55,56] There are some interesting differences, particularly in the presence
of major levels of structures consisting of lactose elongated with
(β1–3) galactose units. Also, the presence of the 6′
isotope of LNT (iLNT) in goat milk indicates that, contrary to the
human biosynthetic pathway, the GlcNAc(β1–3)Gal epitope
is not required for the attachment of a 6′-GlcNAc residue.
Also, the structure Gal(β1–3)[GlcNAc(β1–6)]Gal(β1–4)Glc
may be formed by transfer of Gal(β1–3) to iLNT or alternatively
by transfer of GlcNAc by a separate Iβ6GlcNAcT enzyme, as observed
in lactating tammar wallaby.[57] The human
biosynthetic pathway does not include enzymes for Gal(β1–3),
with Gal(β1–4) disubstitution on a GlcNAc residue, which
has been tentatively observed in goat milk.[24] It should be noted that the first elucidation of this structure
is tentative, because the papers identifying this structure initially
contained mistakes in other structures. The goat structures indicate
activity of ST8Sia, to generate Sia(α2–8)Sia epitopes,
with either Neu5Ac or Neu5Gc residues. Activity of such ST8Sia transferases
in the mammary gland of lactating goats was observed in a comprehensive
transcriptomics study.[55] Finally, the goatmilk oligosaccharides contain some Gal(α1–3)Gal and GalNAc(α1–3)Gal
glycotopes that are absent in human milk.
Quantitative Aspects of
gMOS
Milk is a complex fluid, containing many classes of
biomolecules
(Figure ). A major
class is carbohydrates, of which the majority is usually lactose.
The second class of carbohydrates in human milk is that of hMOS, while
in bovine milk, this is monosaccharides, with bMOS constituting the
third carbohydrate class.[58,59] For goat milk, the
concentrations of monosaccharides have not been extensively studied,
but one study puts them at a comparable level with gMOS.[34] Analysis of milk oligosaccharides often requires
extraction of MOS prior to analysis. The extraction procedure and
required level of purity depend upon the analytical methods, which
are, in turn, determined by the research question. For identification
of specific, unknown structures, the compounds need to be isolated
in pure form for further analysis. A recent review outlines the challenges
and pitfalls in analysis of hMOS.[53] The
most common methods for hMOS analysis have been described in detail
here, and the same challenges hold for gMOS analysis. In short, many
analytical methods have been employed, and particularly, comprehensive
quantitative analysis is difficult. The risk of loss of MOS in the
extraction phase is one major issue that has been understudied thus
far. Also, the choice of analytical method determines to a large part
the precision of quantitation. While for human milk many studies have
been performed, a wide variation in quantitative results has been
observed.[3] Some of the variation can be
explained by population-based differences[60] or genetic variation between individuals.[53] For goats, as well, the breed and geographical factors may influence
the results. It is, however, also possible that differences in analytical
approaches yield deviating results.Several studies have been
performed quantifying gMOS or comparing
MOS quantities between domesticated animal species. In a comparative
study between goat, sheep, and cow milk, quantification was based
on standards using high-pressure/pH anion-exchange chromatography
coupled with pulsed amperometric detection (HPAEC–PAD).[29] They found that the mature Murciano-Granadina
goat milk contained 250–300 mg/L gMOS, representing about 5
times the amount of bMOS measured in cow milk (30–60 mg/L)
and about 10 times more than sMOS in sheep milk (20–40 mg/L)
in the same study.[29] Another study on this
breed investigated the levels of gMOS in colostrum and mature milk
of four individual goats as well as a pooled milk sample from 12 goats.[37] A large variation in total gMOS levels was observed
in colostrum of the four individual Murciano-Granadina goats and the
pooled colostrum, ranging from 251 to 572 mg/L (Table ).[37] Total neutral
gMOS levels ranged from 140 to 315 mg/L, and total acidic gMOS levels
ranged from 83 to 251 mg/L. The most abundant gMOS were galactosyllactoses,
with values ranging from 128.7 to 274.3 mg/L. Higher 2′-FL
concentrations (2.2–31.6 mg/L) were measured in comparison
to fucosyllactosamine (3.1–6.15 mg/L). Furthermore, the authors
noted that, similar to human milk, all five colostrum samples contained
higher 6′-SL concentrations (29–124 mg/L) than 3′-SL
(3–12 mg/L).[37] It should be noted
that several other gMOS studies showed opposite findings, identifying
predominant levels of 3′-SL instead.[25,26,61] Also, in one study on human milk in Vietnam,
specific individuals were identified with predominantly 3′-SL
or near equal levels of 3′-SL and 6′-SL rather than
a clear predominance of 6′-SL.[62]
Table 1
Overview of Average Levels of gMOS
Determined in Quantitative Studies from Different Breeds, Murciano-Granadina
(MG), New Zealand Saanen (NZS), Alpine (A), Garganica (G), Maltese
(M), and Saanen (S)
breed
gMOS (mg/L)
methoda
comments
reference
MG
250–300
HPAEC–PAD
(29)
MG
251–572
HILIC–MS
acidic, 83–251 mg/L; neutral, 140–315 mg/L
(37)
NZS
260–320
LC–MS
colostrum, ∼320 mg/L; mature milk, ∼260 mg/L
(34)
A
1110–1250
GC–MS
monosaccharide-analysis-based method; high levels of Glc and Gal suggest significant levels of
lactose
(27)
G
240–700
HPAEC–PAD
only 3′-SL, 6′-SL, and DSL; colostrum, 700 g/L; mature milk, 240 g/L
(25)
M
190–625
HPAEC–PAD
only 3′-SL, 6′-SL, and DSL; colostrum, 625 mg/L; mature milk, 190 g/L
(25)
S
125–365
HPAEC–PAD
only 3′-SL, 6′-SL, and DSL; colostrum, 365 g/L; mature milk, 125 g/L
(26)
MG
112–488
HILIC–MS
colostrum, 488 mg/L; mature
milk, 112–178 mg/L
(28)
MG
703–2398
LC–MS
first 4 days of lactation; day 1, 2400 mg/L; day 4, 700 mg/L
(30)
HPAEC–PAD, high-performance/pH
anion-exchange chromatography–pulsed amperometric detection;
GC–MS, gas chromatography–mass spectrometry; LC–MS,
liquid chromatography–mass spectromtery; and HILIC–MS,
hydrophilic interaction chromatography–mass spectrometry.
HPAEC–PAD, high-performance/pH
anion-exchange chromatography–pulsed amperometric detection;
GC–MS, gas chromatography–mass spectrometry; LC–MS,
liquid chromatography–mass spectromtery; and HILIC–MS,
hydrophilic interaction chromatography–mass spectrometry.Other studies on gMOS concentrations
in New Zealand Saanengoats
showed ∼320 mg/L in colostrum and ∼260 mg/L in mature
milk (Table ).[34] This study applied liquid chromatography with
mass spectrometric detection (LC–MS), separating structures
on a porous graphitized carbon (PGC) column. Quantitation was achieved
in relation to a calibration curve of commercial standards (4′-GL,
3′-SL, 6′-SL, 3-FL, 2′-FL, LNH, DSL, lactose-1P,
and GOS from Yakult). Only structures fitting m/z of these compounds were taken into account for the quantitation.
This might result in some underestimation of gMOS, because other structural
compositions were not taken into account.Quantitation was also
performed in a comparative study between
Alpinegoats that were either capable or incapable of producing αs1-casein.[27] In the study, the milk
of eight A/A goats (capable of producing αs1-casein)
was compared to the milk from eight O/O goats (null mutant). The study
observed a broad spread in concentrations for each group with 1110
± 290 mg/L for A/A goats and 1250 ± 320 mg/L for O/O goats
(Table ) but no statistically
significant difference between groups. These values are significantly
higher than the values observed in the aforementioned studies,[25,26,28,29,37] and the applied method relies on monosaccharide
quantitation by gas chromatography coupled to MS, showing almost equivalent
amounts (44.2–46.9 mol %) of Gal and Glc in all samples, suggesting
a significant portion of remaining lactose as part of the gMOS fraction.[27]A series of studies by Claps et al. analyzed
the concentrations
of 3′-SL, 6′-SL, and DSL in the colostrum and mature
milk of Garganica (n = 15), Maltese (n = 20), and Saanen (n = 5) goats, using a HPAEC–PAD
method with external standard calibration.[25,26] Significant differences in the levels of the three sialyloligosaccharides
were found between the breeds (Figure and Table ).
Figure 3
Average levels (mg/L) of 3′-SL, 6′-SL, and DSL in
milk of (A) Garganica, (B) Maltese, and (C) Saanen goats over time
and adapted from Claps et al.[25,26]
Average levels (mg/L) of 3′-SL, 6′-SL, and DSL in
milk of (A) Garganica, (B) Maltese, and (C) Saanengoats over time
and adapted from Claps et al.[25,26]Garganica colostrum and milk samples contained higher concentrations
of 3′-SL and 6′-SL than Maltese and Saanengoat colostrum,
whereas the DSL content was highest in colostrum from Saanengoats.
In the first 24 h after kidding, a significant increase in the 3′-SL
concentration in the milk of all three breeds was observed, followed
by a decline toward mature milk.[25,26] The same pattern
was observed for 6′-SL concentrations for the three goat breeds.
The DSL content in Garganica (137.9–126.4 mg/L) and Saanen
(150.0–113.9 mg/L) goat colostrum dropped slightly in the first
24 h, from 137.9 to 126.4 mg/L and from 150.0 to 113.9 mg/L, respectively,
but significantly increased in colostrum of Maltese goats, from 104
to 228 mg/L (Table ). Toward mature milk, the DSL levels gradually decreased for all
breeds (Figure ).
The general trend of decrease in MOS concentrations from colostrum
toward mature milk is found in common also with hMOS and bMOS.[22,63] A recent study comparing Saanengoats to local Guanzhong goats at
40–50 days of lactation showed similar levels of 3′-SL,
17.17 mg/L in Guanzhong and 18.51 mg/L in Saanen, while 6′-SL
and DSL are significantly increased in Guanzhong goats, i.e., 33.41
mg/L 6′-SL versus 9.98 mg/L in Saanengoats and 1.16 mg/L DSL
in Guanzhong versus 0.39 mg/L in Saanen.[64] The Claps studies on Saanengoats showed much higher concentrations
at 90 days postpartum.[26]Saanengoats
have a high frequency of defective alleles at the
αs1-casein locus, and this is associated with a low
αs1-casein content in milk (450 mg/L compared to
up to 8.4 g/L).[26,65] On the basis of these results,
Claps et al. speculated that the defective αs1-casein
production negatively affected the whole secretion process of milk
constituents, including the synthesis of sialyltransferases and, thus,
the production of sialylated gMOS. This is in contrast, however, with
the findings from Meyrand et al., where no significant differences
in acidic gMOS concentrations were observed between Alpinegoats with
and without αs1-casein deficiency.[27]Claps and co-workers also investigated the influence
of parity
on the sialyl gMOS content in colostrum and milk.[26] Goat milk samples from five goats in second parity and
five goats in third parity were analyzed, showing only a significant
difference in 3′-SL concentrations between second and third
parity, with values of 203 and 125 mg/L, respectively.[26] A recent study has shown that, in protein glycosylation
of goat milk glycoproteins, fucosylation and sialylation increase
with parity.[66]Martín-Ortiz
et al. examined gMOS levels in milk of Murciano-Granadina
goats at different lactation stages.[28] Eight
major gMOS (3′-SL, 6′-SL, sialyllactosamine, three glycolylneuraminyllactose
isomers, and two galactosyllactose isomers) were quantified with hydrophilic
interaction chromatography–quadrupole–mass spectrometry
(HILIC–Q–MS), and 49 gMOS structures were monitored.A comparison between milk of a single goat and a pooled milk sample
from eight goats showed a considerable difference in total gMOS between
the individual goat (GM) and the pooled milk (GP) samples of 58.9
and 178.1 mg/L, respectively (Table ).[28] This large difference
in results between the individual goat and the pooled milk shows the
large variability in gMOS composition between individual goats of
the same species. Similar to results from Claps et al., over time,
concentrations of the most abundant gMOS were highest at the beginning
of lactation and decreased with lactation time.[25,26] In Murciano-Granadina goats, 6′-SL was by far the most abundant
acidic gMOS in the pooled samples, whereas in the individual goat
samples, 3′-SL levels almost reached those of 6′-SL.
Also notably, 3′-SL in pooled milk of Saanen, Garganica, and
Maltese goats was the most abundant gMOS.[25,26]The concentration of neutral gMOS (265.2 mg/L) was higher
than
that of acidic gMOS (222.8 mg/L) in the beginning of lactation but
rapidly dropped with lactation time, mainly as a result of a significant
decrease in galactosyllactose isomers, the most abundant neutral gMOS.
The acidic gMOS content also decreased with lactation time but not
as much as that of the neutral gMOS, resulting in higher acidic (149.3
mg/L) than neutral (28.8 mg/L) gMOS concentration at 30 days of lactation.
Notably, the concentrations of 3′-SL are much lower than those
observed in the three other goat species, while the 6′-SL levels
at day 1 are comparable to that of the Maltese goats. The levels of
6′-SL remain higher in the Murciano-Granadina goats. In this
study, also three Neu5Gc–lactose isomers were monitored, without
giving specific structures. These oligosaccharides were only observed
at relatively low levels (together ∼25–50 mg/L) and
do not seem to follow the same concentration trend over time as analogous
compounds containing Neu5Ac. The concentrations of two neutral galactosyllactose
structures, most likely 3′-GL and 6′-GL, were also measured,
ranging from ∼30 to 270 mg/L; approximately half of the gMOS
determined in this study were neutral. In the study by Albrecht et
al., the analysis of acidic versus neutral structures showed 95% acidic
structures in goat milk.[24] Other reports
also state that acidic oligosaccharides are the major component in
goat milk.[25,45] It is possible that the levels
of acidic versus neutral gMOS are strongly affected by goat breed,
suggesting the potential for a comprehensive and comparative study
of goat milk from different breeds.A recent study on goat colostrum
composition analyzed lipid and
oligosaccharide composition and concentration.[30] This paper showed levels decreasing from 2398.4 mg/L at
day 1 to 702.7 mg/L at day 4 of lactation, markedly higher than in
other studies thus far (Table ).When all quantitative studies on gMOS are taken into
account (Table and Figure ), a very broad range
of concentrations
has been reported. The lowest value measured in a single goat was
58.9 mg/L in mature milk and ∼200 mg/L in early colostrum.[28] The highest values in mature milk were observed
in a single study on Saanengoats at 1110–1250 mg/L.[27] The methodology of this study, however, seems
to have incorporated a significant amount of lactose into the quantitation
and should therefore be discounted as an assessment of gMOS quantity.
The highest colostrum values were ∼2.4 g/L in Murciano-Granadina
goats.[30] On average, the values reported
range from ∼100 to 250 mg/L in mature milk and from ∼300
to 2400 mg/L in colostrum across different breeds. Interestingly,
one study on bovine milk showed that the major oligosaccharides, i.e.,
3′-SL, 6′-SL, and 6′-SLN, start at high concentrations
in colostrum, i.e., 855 mg/L for 3′-SL, 117 mg/L for 6′-SL,
and 141 mg/L for 6′-SLN, followed by a rapid decrease.[67] An ultrafiltrate of whey permeate was shown
to contain particularly high levels of bMOS, indicating that processing
streams may be a promising source of dairy-derived MOS.[68] A comparison of MOS composition of goat milk
with human, bovine, and sheep milk shows that, in both the colostrum
phase as well as mature milk phase, the quantities of gMOS are higher
than those for bovine and sheep milk but still far lower than those
in human milk (Figure ). The physiological and molecular basis for these variations in
gMOS concentrations remains to be elucidated. It should be noted that
quantitative studies on hMOS also vary greatly, and recent recommendations
were to evaluate different methods in a cross-laboratory study to
determine how much of the variation is caused by experimental bias.[3,53] A similar recommendation could be made for analysis of goat milk
oligosaccharides.
Figure 4
Comparison of acidic and neutral MOS concentration levels
between
human (blue), goat (green), cow (purple), and sheep (red) colostrum
(Col) and mature milk (Mat). For sheep colostrum, there are no data
(n.d.) available. The open part of the bars shows the highest concentration
level reported, and the filled part of the bars represents the lowest
reported concentration.[3,25,26,29,30,37,60,63]
Comparison of acidic and neutral MOS concentration levels
between
human (blue), goat (green), cow (purple), and sheep (red) colostrum
(Col) and mature milk (Mat). For sheep colostrum, there are no data
(n.d.) available. The open part of the bars shows the highest concentration
level reported, and the filled part of the bars represents the lowest
reported concentration.[3,25,26,29,30,37,60,63]
Functional Analysis of Milk Oligosaccharides
Currently, increasing evidence is generated for specific functions
of specific hMOS, being antiadhesive, immune-modulating, or a targeted
prebiotic for specific desirable bacterial/microbiota strains in early
infant development.[16] At the moment, there
is a lack of studies into the required concentrations of hMOS to achieve
optimal functionality. Also missing in the current understanding is
the level of diversity required for optimal health effects in the
infant development. The addition of a single hMOS structure as a supplement
to infant formula clearly has benefits, as observed for the additions
of 2′-FL.[69,70] When gMOS and bMOS composition
is observed, it is clear that goat milk shows more similarities with
hMOS composition than bMOS.[24,27,29,37] It should be noted, however,
that there is still a significant difference between gMOS and hMOS.
One particular difference is the dominance of acidic MOS in goat milk
compared to human milk (Figure ). Moreover, the neutral fraction of hMOS is dominated with
fucosylated structures, while gMOS contain only minor levels of fucosylated
neutral structures (Figure ). Figure shows a comparison of structures and relative quantities based on
the study by Albrecht et al. for goat milk[24] to term and preterm human milk on the basis of the study by Austin
et al.[63] Although the composition of hMOS
is significantly different from gMOS, there are sialylated, neutral
non-fucosylated, and neutral fucosylated structures in common between
the two. Therefore, in comparison to bMOS and sMOS, gMOS have more
potential as a functional substitute for hMOS. Moreover, the levels
of gMOS are significantly higher than those of bMOS and sMOS, suggesting
that goat milk has more potential as a source for such functional
oligosaccharides.
Figure 5
Overview of relative intensities of gMOS derived from
Albrecht
et al.[24] compared to hMOS in term and preterm
milk derived from Austin et al.[63] Clockwise
from the top, first, acidic oligosaccharides are grouped together,
presented according to relative abundance, followed by neutral oligosaccharides
in order of abundance. Structures similar between human and goat milk
are presented in bold, and corresponding segments are offset from
the ring chart.
Overview of relative intensities of gMOS derived from
Albrecht
et al.[24] compared to hMOS in term and preterm
milk derived from Austin et al.[63] Clockwise
from the top, first, acidic oligosaccharides are grouped together,
presented according to relative abundance, followed by neutral oligosaccharides
in order of abundance. Structures similar between human and goat milk
are presented in bold, and corresponding segments are offset from
the ring chart.
Prebiotic Potential
Thum and co-workers
used a previously
obtained gMOS-enriched fraction (labeled CMOF in their work)[34] in a study to investigate the growth of bifidobacteria
that were isolated from the feces from breast-fed infants.[71] It should be noted that processing conditions
and use of β-galactosidase in the enrichment of gMOS has some
influence on the composition of the oligosaccharide mixture.[72] A total of 17 strains of bifidobacteria were
isolated from infant feces, and their growth on gMOS was analyzed
in comparison to GOS, FOS, inulin, and 3′-SL or 6′-SL.[71] All bifidobacteria grew faster and reached higher
optical densities on the gMOS compared to the other substrates. No
growth was observed on medium supplemented with inulin. Interestingly,
one Bifidobacterium bifidum strain
was able to use 3′-SL or 6′-SL as the sole carbon source,
whereas the other B. bifidum strains
were able to ferment the gMOS-enriched fraction while partially degrading
3′-SL and 6′-SL in the gMOS. Carbohydrate depletion
after 36 h of incubation was evaluated by LC–MS and HPLC analysis.
Two B. bifidum strains (AGR2166 and
AGR2168) used more gMOS than Bifidobacterium breve or Bifidobacterium longum subspecies longum isolates, and this was related to an enhanced
sialidase activity. Furthermore, for gMOS, the in vitro production of lactate and SCFAs, such as acetate, compared better
to other fermentable substrates.[71] These
SCFAs are important substrates for gut health and gut microbiota.[73,74] The production of SCFAs by beneficial bacteria has been linked to
protection against several pathologies on the long term, including
cardiovascular disease, inflammatory bowel disease (IBD), metabolic
syndrome, and even some types cancer.[75−77] Butyrate is an important
SCFA and considered the preferred energy source for colonocytes.[78] Incubation of B. longum subsp. infantis with gMOS has also
shown increased adhesion to HT-29 cells of more than 8-fold compared
to controls and more than 2.5-fold better than immunoglobulin G (IgG)-enriched
bovine whey.[61] The authors of that study
used the same gMOS mixture, rich in 3′-SL, in a study showing
enhanced SCFA production when B. longum susbsp. infantis is incubated with
gMOS. Moreover, the pre-incubation with gMOS enhanced the ability
of B. longum subsp. infantis to inhibit Campylobacter
jejuni infection of HT-29 cells.[79]The prebiotic potential of gMOS was confirmed in
another study.[80] Here, bifidobacteria Bifidobacterium animalis and B. longum strains were tested as well as Lactobacillus casei and Lactobacillus acidophilus strains.
The growth rate of both bifidobacteria strains as well as L. casei was higher with gMOS isolated from goat-milk-derived
infant formula than with the established GOS prebiotic (p < 0.05).[80] It should be noted that
both prebiotic studies have only tested probiotic species in monoculture
and have not assessed growth of pathogens and/or commensal species
nor assessed interspecies competition in mixed culture experiments.
A shift toward more probiotic species in a mixed culture or in vivo is required to fully substantiate a prebiotic function.An in vivo study by Thum et al. determined the
effect of prenatal consumption of gMOS (CMOF) on the colon microbiota
and milk composition of pregnant mice.[81] The development of the mice offspring and whether these effects
in offspring persisted after 30 days of consuming the control diet
were also determined. The diet did not affect the food intake, body
weight, gastrointestinal tract (GIT) length, small intestine length,
or weight of stomach, colon, spleen, kidneys, brain, femur, and visceral
fat of the dam. However, in comparison to negative-control-diet- and
GOS-diet-fed dams, the gMOS-diet-fed dams had an increased colon length
and lower liver weight at 30 days after delivery. The pups of the
gMOS-fed dams had increased body weight and length at weaning, similar
to GOS control pups. However, only pups of gMOS-fed dams had an increased
microbial diversity and relative abundance of bifidobacteria at weaning
as well as higher levels of the SCFAbutyric acid in the colon. Bifidobacteria
produce acetate and lactate, which can be converted into butyrate
by other bacteria.[82] It was concluded that
consumption of gMOS by the dams during gestation and lactation improved
the development of the offspring and the relative abundance of bifidobacteria
in the colon at weaning. Although there is currently no data on human
interventions with gMOS, studying the potential prebiotic effects,
the studies thus far suggest prebiotic potential more closely resembling
hMOS than GOS. This may be explained by the structural overlap between
gMOS and hMOS (Figure ). There is currently no intervention study with gMOS; a study with
bMOS has been performed, using a bMOS enriched whey permeate, obtained
through ultrafiltration and anion-exchange chromatography. The bMOS
product is well-tolerated by healthy adults in a single-blind placebo-controlled
study.[83,84] The bMOS were fully digested by the intestinal
microbiota but did not illicit a significant change in the microbial
transcriptome nor on the exfoliated gut epithelia.[84] There was only a short-term effect on bifidobacterial levels,
showing an increase after 4 days of intervention but no longer after
11 days.[83] The product contained mostly
3′-SL and to a lesser extent 6′-SL,[85] fitting the composition observed for bovine milk.[24] It should be noted that recent advances in hMOS
synthesis technology have allowed for sufficient levels of 2′-FL
and LNnT to be produced, leading to the first European Food Safety
Authority (EFSA)-approved infant formulas supplemented with these
hMOS for functionality. Tests thus far have shown that the addition
of 2′-FL and LNnT shifts the microbiota more toward breast-fed
compositions than formulas with GOS and FOS.[86,87] Moreover, analysis of goat milk has shown the presence of both 2′-FL
and LNnT, underscoring the potential of goat milk as an infant formula
ingredient.
Anti-inflammatory Effects
Goat milk
oligosaccharides
have shown to be anti-inflammatory in a rat model of hapten-induced
colitis. Daddaoua et al. investigated the role of gMOS in a model
of experimental colon inflammation induced by the hapten, trinitrobenzenesulfonic
acid (TNBS), in rats.[88] TNBS-induced colon
inflammation is characterized by anorexia with body weight loss, epithelial
necrosis, bowel wall thickening, and colon shortening. For the treatment
of rats, an enriched gMOS permeate of Martinez-Ferez et al. was used.[89] This permeate contains ∼200–240
mg/L gMOS but also ∼2.25 g/L lactose. Rats that were fed with
500 mg of the lyophilized gMOS permeate/kg of body weight per day
showed significantly less symptoms compared to control rats that did
not receive the gMOS. Downregulation of colonic expression of inflammatory
factors interleukin 1β (IL-1β) and inducible nitric oxide
synthase (iNOS) was also observed as well as reduced cyclooxygenase
2 (COX2), which is not directly involved in inflammation but can be
used as a marker for inflammation.[88] Because
the gMOS sample still contained a lot of lactose, it is unclear whether
all of the observed effects are only caused by gMOS or if lactose
also had an effect.[88]Lara-Villoslada
et al. also studied the effect of gMOS on colon inflammation in rats
induced by dextran sodium sulfate (DSS).[90] They also used the enriched gMOS permeate produced by Martinez-Ferez
et al. but first removed the residual lactose from the gMOS fraction.
The body weight gain and food intake of rats fed with gMOS (PF-GMO)
were similar to the control rats that did not receive gMOS (PF-control).
Interestingly, the colonic content of probiotic lactobacilli and bifidobacteria
was significantly higher in the rats receiving gMOS but not of the
potential pathogens. After DSS treatment, histological analysis showed
that the gMOSrats (DSS-GMO) had no ulceration and recovered from
inflammation, while the DSS control rats had significant ulceration
and inflammation. Also, blood granulocyte levels were reduced in gMOS-fed
rats compared to control rats. In gMOS-fed rats, the levels of myeloperoxidase
activity, a proxy for neutrophil infiltration, do not increase upon
DSS treatment, while in control rats, a 5-fold activity increase is
observed upon DSS treatment.[90]Both
studies indicated that gMOS reduce intestinal inflammation
and contributed to the recovery of damaged colonic mucosa and suggested
gMOS as a suitable treatment of inflammatory bowel disease. Previous
studies showed that GOS, which are commonly added to infant formula
to substitute hMOS, were unable to reduce inflammation in a rat model
for colitis.[91] Similar studies have not
been performed with hMOS thus far; however, anti-inflammatory effects
have been well-established for hMOS.[16,92]A recent
mini-review showed an overview of hMOS with the potential
for galectin binding and, thus, galectin-directed signaling.[8] Many hMOS have potential galectin recognition
epitopes, i.e., all structures with a non-reducing terminal galactose
linked to a Glc, GlcNAc, or GalNAc residue, with free OH on Gal OH4
and OH6 and a free OH3 on the preceding Glc, GlcNAc, or GalNAc. Other
glycotopes were shown to not fit galectin-binding sites.[93] This interaction may be one of the mechanisms
of hMOS immune modulation.[8] Many of the
structures shown in Schemes and 2 have clear potential for galectin
recognition, marked in green. Galectins play a pivotal role in immune
modulation and inflammatory control.[94] Therefore,
many of the relatively abundant gMOS, such as 3′-GL, LNnT,
LNnH, 3′-SL, and 3′-NGL (Schemes and 2), have potential
immune-modulating and anti-inflammatory effects through galectin interactions.
Detailed studies on galectin specificity have shown, moreover, that
some galectins have enhanced affinity when the Gal residue is sialylated
on the 3 position, e.g., 3′-SL, while affinity for galectin
8-N is even further enhanced for ganglioside GD3, containing a Neu5Ac(α2–8)Neu5Ac(α2–3)Gal
epitope.[93] This epitope is also present
on the gMOS structure DSL (Scheme ). Specifically, a strong interaction of galectin 3-C
for the Gal(α1–3)Gal and GalNAc(α1–3)Gal
glycotopes has also been documented.[93,95] Elevated serum
levels of galectin 3 have been associated with long-term risks in
cardiovascular disease.[96] While human milk
does not contain oligosaccharides with this glycotope, goat milk does
contain a low amount of 3′-α-galactosyllactose (Scheme ). Galectin 9-N
and 9-C binding domains both interact strongly with poly-β1–3-linked
Gal residues, which do not occur in human milk but are present in
goat milk (Scheme ). Where it was previously argued that hMOS might be a powerful tool
to study galectin-binding kinetics and functionality,[8] gMOS might fill some gaps in glycotopes that are absent
in hMOS, further enhancing the understanding of galectin interactions.
Similarly, gMOS might be applied to study the binding of other lectins,
including siglecs, selectins, and DC-SIGN, but also bacterial and
viral glycan adhesion molecules. In the gut, intestinal epithelial
cell-derived galectin 9 has been implicated in GOS/FOS-associated
immunomodulation.[97,98] Galectins are involved in neutrophil
regulation, and triggering of neutrophil response is implicated in
necrosis in colitic inflammation.[99] Stimulation
of galectins by hMOS or gMOS in the gut might play a role in immune
modulation and reducing necrotizing effects of inflammation.Besides galectins, interactions between oligosaccharides and toll-like
receptors (TLRs) in the gut have also been shown. In some studies,
oligosaccharides, including GOS, hMOS, and gMOS, have been shown to
mediate TLR-mediated response.[100−102] In 2013, a mouse study showed
that 3′-SL, which is also abundant in gMOS, interacts with
TLR4, which is normally associated with LPS-mediated inflammatory
response, leading to inflammation.[103] Later,
a study using humanTLR4 was unable to reproduce the effect, concluding
that differences in specificity of mouse and humanTLR4 might be responsible.[104]
Barrier Function
Barnett et al.
studied the effect
of a semi-purified gMOS-enriched fraction of goat milk[34] on the barrier integrity and mucin production
of co-cultures of small and large intestine epithelial cells.[105] They showed that the gMOS-enriched fraction
enhanced the intestinal epithelial barrier function. The trans-epithelial electrical resistance (TEER) increased significantly
and in a dose-dependent manner. Although the researchers did not separately
investigate the effect of other components in the gMOS-enriched fraction,
it is known that lactose, glucose, and galactose have no effect on
TEER as a readout of barrier integrity.[18,19] The gMOS did
not significantly affect the metabolic flux of the epithelial cells.
The expressions of the mucin-synthesizing genes for Muc2, Muc4, and
Muc5AC were only slightly affected by the presence of gMOS, and total
mucin production compared to controls was not different when cells
were incubated with gMOS.[105] The conclusion
was that gMOS did increase the barrier function of intestinal cells
but not through adaptation of metabolic flux or increased mucin production.In a recent publication, different GOS formulations were investigated
for their effect on mucin production and expression of mucin-related
genes.[100] This study observed that GOS
with lactose had a more pronounced effect on the gene expression in
cell lines than GOS that was purified of lactose. A further study
using hMOS observed upregulation of mucin-production-related genes,
MUC2, TFF3, and RETNLB, when LS174T cells were incubated with 3-FL,
while MUC2 and TFF3 were upregulated by lacto-N-triose
(LNT2).[106] Furthermore, under challenge
with tumor nectrosis factor α (TNF-α), interleukin 13
(IL-13), and tunicamycin, differential effects of 2′-FL, 3-FL,
and LNT2 were observed, supporting a direct effect of these structures
on barrier-function-related production of mucin.[106] It should be noted that 3-FL, the most effective modulator,
is not observed in goat milk, while LNT2 and 2′-FL have been
found (Schemes and 2); therefore, a certain level of induction of mucin
production by gMOS may be expected.A recent study using a murine
NEC model observed that hMOS increased
barrier function, by stimulating Muc2 production in the intestine.[107] This was further verified in a human gut epithelial
cell line. Furthermore, it was observed that the protective effect
was mediated through chaperones, particularly protein–disulfide
isomerase; suppression of protein–disulfide isomerase abolished
the effect of hMOS.[107] Lactose controls
also had a noticeable effect on mucin-related gene expression. It
seems that the effect of lowly digestible oligosaccharides on the
mucin production is not straightforward.
Pathogen Inhibition
The pathogen inhibition activity
of hMOS is presumed to be caused by similarity in structures between
hMOS and epithelium-associated glycans.[16] Pathogens present lectin-like receptors that recognize a specific
glycan epitope to adhere to the epithelial layer as a first step in
infection. In the presence of significant levels of hMOS with similar
structural elements, hMOS will bind to these receptors and, thereby,
prevent adhesion.[108] In some cases, the
hMOS block the epithelial receptor to which pathogen glycans adhere.
For example, the HIV gp120 anchor protein presents high-mannose-type
glycans that adhere to DC-SIGN as an adhesion mechanism for the pathogen.[109] DC-SIGN has affinity for high-mannose as well
as fucose-containing glycans, particularly glycans containing a Lex glycotope; i.e., Fuc(α1–3)[Galβ(1–4)]GlcNAc.[110] Human milk contains LNFP III, with a Lex glycotope, as well as Muc1, containing glycans with Lex glycotopes that bind to DC-SIGN, thereby preventing viral
adhesion.[111−113] There is also evidence that 3′-SL
directly interacts with epithelial cells, modulating gene expression
of sialyltransferases, thereby modifying epithelial glycosylation.[114] It has been hypothesized that the altered glycosylation
might result in reduced binding of sialic-acid-specific pathogens.[16] The large diversity of hMOS is thought to exist
because of the large diversity in pathogens.[16,115] It has been shown for N-glycans as well as hMOS
that not only is a specific glycotope required for action, but also
that the presentation of the epitope matters.[116,117] The levels of hMOS are also relevant, because some interactions
require multivalency.[118] This can be achieved
by not only highly complex, branched carbohydrates but also high levels
of smaller oligosaccharides, resulting in indirect multivalency. This
theory was further supported by research showing that the same functional
epitope on different scaffold hMOS has different affinities for pathogen
receptors.[119] Well-established structures
related to decoy effects against pathogens are collected in Table . Although it has
not been established as a pathogen inhibition effect, a microbial
imbalance or pathogenic species is most likely involved in the development
of necrotizing enterocolitis. It is worth noting that the most profound
effects have been observed with disialyl-LNT (DSLNT), which has not
been observed in goat milk. However, protective effects against necrotizing
enterocolitis have also been shown for 2′-FL and sialylated
GOS.[120] While human milk contains only
minor levels of the GOStrisaccharides 3′-GL and 6′-GL[43,121,122] and no sialylated GOS, goat
milk does contain a wider array of GOS structures and several sialylated
GOS structures (Scheme ). These may potentially have similar effects, although the
structural overlap with the sialylated GOS used in the necrotizing
enterocolitis study is limited.[123]
Table 2
Structural MOS Epitopes with Shown
Pathogen Inhibition Functionalitiesa
glycotopeb
pathogen
possible gMOS
reference
Fuc(α1–2)Gal glycotopes
Campylobacter jejuni
maybe
(125)
Candida albicans
maybe
(126)
norovirus
maybe
(127)
3-FL
Escherichia coli
yes
(128)
Salmonella fyris
yes
(128)
Lex (LNFP III)b
HIV
maybe
(111)
LNT
Entamoeba histolytica
no
(129)
Group B Streptococcus
no
(130−132)
Streptococcus pneumoniae
no
(133)
Pseudomonas aeruginosa
no
(130)
LNFP I
Group B Streptococcus
no
(131,132)
LNnT
Streptococcus pneumoniae
yes
(133,134)
Pseudomonas aeruginosa
yes
(130)
3′-SL
Escherichia coli
yes
(128)
influenza B
yes
(130)
Helicobacter
pylori
yes
(135)
Pseudomonas
aeruginosa
yes
(136)
6′-SL
influenza A
yes
(130)
Salmonella fyris
yes
(128)
Escherichia coli
yes
(128)
Pseudomonas aeruginosa
yes
(136)
general hMOS
Vibrio cholera
maybe
(128)
The presence of a certain glycotope
in gMOS is provided.
3-FL,
3-fucosyllactose; LNT, lacto-N-tetraose; LNFP I,
lacto-N-fucopentaose
I; LNnT, lacto-N-neotetraose; 3′-SL, 3′-sialyllactose;
and 6′-SL, 6′-sialyllactose.
The presence of a certain glycotope
in gMOS is provided.3-FL,
3-fucosyllactose; LNT, lacto-N-tetraose; LNFP I,
lacto-N-fucopentaose
I; LNnT, lacto-N-neotetraose; 3′-SL, 3′-sialyllactose;
and 6′-SL, 6′-sialyllactose.Recently, it was shown that gMOS can trigger bifidobacteria
to
inhibit C. jejuni infection in an in vitro study, showing a form of indirect pathogen inhibition.[79] Two recent studies have investigated the direct
antiadhesive capacity of isolated gMOS. One study observed reduced
adhesion of Escherichia coli and Salmonella typhimurium to CACO-2 cells when pre-incubated
with gMOS.[80] This was observed independent
of beneficial microbiota. The second study showed the same results
with Salmonella by green fluorescent
antibodies against the Salmonella strain
used.[124] Here, the effect of sialylated
gMOS was shown to be stronger than that of neutral gMOS. Although
not all structures in Table are present in similar quantities in goat milk as in human
milk, hypothetically, some functionalities may also occur with other
gMOS if they present the suitable glycotopes as well as with hMOS.
Further research into functionality of hMOS as well as non-humanMOS
would be beneficial for the development of the field.
Authors: Clemens Kunz; Christina Meyer; Maria Carmen Collado; Lena Geiger; Izaskun García-Mantrana; Bibiana Bertua-Ríos; Cecilia Martínez-Costa; Christian Borsch; Silvia Rudloff Journal: J Pediatr Gastroenterol Nutr Date: 2017-05 Impact factor: 2.839
Authors: Ann E Lin; Chloe A Autran; Alexandra Szyszka; Tamara Escajadillo; Mia Huang; Kamil Godula; Anthony R Prudden; Geert-Jan Boons; Amanda L Lewis; Kelly S Doran; Victor Nizet; Lars Bode Journal: J Biol Chem Date: 2017-04-17 Impact factor: 5.157
Authors: Sander de Kivit; Aletta D Kraneveld; Leon M J Knippels; Yvette van Kooyk; Johan Garssen; Linette E M Willemsen Journal: J Innate Immun Date: 2013-05-28 Impact factor: 7.349
Authors: Wenjing Lu; Wenjuan Du; Victor J Somovilla; Guangyun Yu; Diksha Haksar; Erik de Vries; Geert-Jan Boons; Robert P de Vries; Cornelis A M de Haan; Roland J Pieters Journal: J Med Chem Date: 2019-06-28 Impact factor: 7.446
Authors: Christoph Bührer; Regina Ensenauer; Frank Jochum; Hermann Kalhoff; Berthold Koletzko; Burkhard Lawrenz; Walter Mihatsch; Carsten Posovszky; Silvia Rudloff Journal: Mol Cell Pediatr Date: 2022-07-13
Authors: Ankita Jena; Carlos A Montoya; Wayne Young; Jane A Mullaney; Debashree Roy; Ryan N Dilger; Caroline Giezenaar; Warren C McNabb; Nicole C Roy Journal: Front Neurosci Date: 2022-08-15 Impact factor: 5.152